http://www.businesswire.com/news/home/20120509005593/en/Arrowhead-Presents-Data-DPC-System-Hepatitis-Program
Can you paste the full article? The link doesn't give access to the full article for those of us who are premium members.
What I can see is that Arrowhead expects to file an IND (Investigational New Drug) to begin human testing of the HBV candidate “late in the second quarter” of 2013.
This is a new drug, not GS9620, not Myrcludex. This one actually looks more promising than either of those two. It's a RNAi that works under the same theory of ridding the surface antigen
what drug did they use?gs9620, myrcludex, rna interf?
Another new news (09 May 2012) from Arrowhead:
http://www.genomeweb.com/rnai/arrowhead-aims-hbv-ind-early-2013-releases-preclinical-data-program
It was mentioned in the article that: ... transiently transgenic HBV mouse model resulted in a multi-log reduction of serum HBsAg and serum HBV DNA.
And: .... Using a transgenic mouse model of chronic HBV infection in collaboration with Dr. Alan McLachlan at the University of Illinois-Chicago, dramatic reductions in viral transcripts, viral replicative DNA intermediates, and intracellular HBV core antigen were observed in the liver after two weekly doses.
So we are really against not HBV but the greed and immoralities of pharmaceuticals and humanities in general?
becuase if you cure a disease you ll get less money from patients
http://www.arrowheadresearch.com/pdf/whitepaper-hbv-3-7-12.pdf
CEO of replicor:
"We need to perform more studies but the plans is for the drug to be made available as soon as possible. There is no clinical trial plans yet for the USA."
I wonder why? If the drug is so hopeful, why don't some big pharmaceuticals jump on it?
Don't have any info on Myracludex, but there is another drug being developed by Arrowhead Research that looks just as promising, if not more so than both Rep 9AC and Myracludex B.
Hi,
what about myracludex????
Thanks A lot,,,
i think we should ask them to possibility of being part of trials in asia even by paying the drug ourselves since we already know it is much less toxic than interferon and other hbv treatments
i d also ask possibility of use combo with antivirals and interferon all paid by us
I emailed the CEO of replicor 2 weeks ago re Rep 9AC. This is his response:
We need to perform more studies but the plans is for the drug to be made available as soon as possible. There is no clinical trial plans yet for the USA.
Michel Bazinet.